Thursday, November 12, 2026

Coffee Futures Went Up By Over 7% In The Last 10 Sessions

Coffee Futures Went Up By Over 7% In The Last 10 Sessions

(VIANEWS) - Coffee (KC) has been up by 7.13% for the last 10 sessions. At 23:50 EST on Wednesday, 2 August, Coffee (KC) is $166.80.

Volume

Today's last reported volume for Coffee is 0, 100% below its average volume of 19600.16.

Volatility

Coffee's last week, last month's, and last quarter's current intraday variation average was a positive 0.95%, a negative 0.22%, and a positive 2.03%, respectively.

Coffee's highest amplitude of average volatility was 2.45% (last week), 1.64% (last month), and 2.03% (last quarter), respectively.

Commodity Price Classification

According to the stochastic oscillator, a useful indicator of overbought and oversold conditions, Coffee's commodity is considered to be oversold (<=20).

News about

  • Crude oil forecast August 2023 - 01 August 2023. According to DailyForex on Tuesday, 1 August, "Over the last several weeks, the West Texas Intermediate Crude Oil market has rallied rather significantly during the month of July, and now that we head into August, one has to wonder whether or not we can continue to see the upward pressure. "
  • According to DailyForex on Tuesday, 1 August, "S Fed will become less aggressive, the higher price of Crude Oil may affect inflation data in the coming weeks too, this could also play into the value of the EUR/USD in August."

More news about Coffee (KC).

ViaNews Editorial Team

Via News Editorial Team delivers comprehensive financial news coverage and market analysis from journalists around the world. Our team specializes in data journalism and in-depth reporting on stock markets, business developments, and economic trends.

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Biotech Catalyst Wave: Late-2026 Clinical Readouts, PDUFA Dates and Capital Restructuring
A dense cluster of Q4 2026 to Q1 2027 clinical and regulatory catalysts spans hepatitis delta (Vir's ECLIPSE/SOLSTICE), hypertension and sleep apnea (Mineralys' lorundrostat, PDUFA 2026-12-22), severe hypertriglyceridemia (plozasiran), oncology (ivonescimab BLA, PDUFA 2026-11-14) and gene therapy (Krystal). Positive data flow from AASLD and AHA presentations is offset by cost-cutting guidance, milestones slipping into 2027, and a delisting process that signals capital-market stress for some issuers. Near-term value hinges on binary FDA decisions and Phase 3 topline readouts in Q1 2027.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
Ford Motor Company
Both facts give cash for Ford Motor Company at the same point in time (2025-12-31; FY 2025 year-end and Q4 2025 year-end are the same date). Both are labelled USD, but the values are 23,356,000,000 and 23.356, which cannot both be true in USD. The two numbers agree once the second is read as billions (23.356 bn = 23,356,000,000), so the economic content is consistent and the conflict is a unit/scale error in the Q4 2025 record. The period is not the reason for the conflict: a Q4 and an FY figure at the same year-end date should match.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,995
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,995 facts checked against source5,565 source documents archived
Query this data → isubstrate.com